ArticleFrontiers in nutrition2025
MIND diet score and its association with metabolic dysfunction-associated steatotic liver disease and gut microbiota profiles: a cross-sectional study.
Article in Frontiers in nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Associations of Mediterranean, DASH, and MIND diet adherence with metabolic parameters in individuals with type 2 diabetes mellitus: a cross-sectional study.Irish journal of medical science · 2026Article
- Research advances on gut microbiota dysbiosis and chronic liver diseases: a review.Frontiers in medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) is a rising health issue linked to poor diet and gut microbiota dysbiosis. The Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND) diet, high in polyphenols and anti-inflammatory nutrients, may help protect against MASLD. This study examined how adherence to the MIND diet relates to MASLD severity, focusing on hepatic steatosis, fibrosis, insulin resistance, inflammation, and gut microbiota diversity. Methods: A cross-sectional analysis of 450 adults with confirmed MASLD was conducted. MIND diet scores were derived from a validated FFQ. Hepatic outcomes were assessed via ultrasonography, hepatic steatosis index (HSI), controlled attenuation parameter (CAP), and fibrosis-4 (FIB-4) index. Biomarkers included liver enzymes (ALT, AST, GGT, and ALP), HOMA-IR, lipid profile, C-reactive protein (CRP), lipopolysaccharide (LPS), and trimethylamine N-oxide (TMAO). Gut microbiota composition was analyzed using 16S rRNA sequencing. Results: Higher MIND scores were associated with reduced steatosis as measured by HSI and CAP, lower fibrosis indicated by the FIB-4 index, improved insulin sensitivity reflected by lower HOMA-IR values, decreased liver enzyme levels, and a more favorable lipid profile. Inflammatory markers (CRP, LPS) decreased with higher adherence (all Conclusion: Greater adherence to the MIND diet was associated with indicators of better liver function, lower systemic inflammation, and improved metabolic health, and a more favorable gut microbiota composition in adults with MASLD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.